Clinical Trial

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-12; most recent amendment 2025-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-04
Trial Details
NCT Number NCT06738251
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Urothelial Carcinoma
Enrollment 402 participants
Start Date 2025-02-12
Primary Completion 2026-07 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-07-17